导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.98% | 3295/4763 |
| 近一周 | -1.11% | 1689/5452 |
| 近一月 | -1.18% | 1056/5409 |
| 近一季 | 0.57% | 888/5219 |
| 近半年 | -0.97% | 1635/4908 |
| 近一年 | - | 2762/4388 |
| 近两年 | 36.17% | 2064/2951 |
| 近三年 | 23.89% | 1348/2250 |
| 成立以来 | 80.49% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.56% 4234/4961 |
6.57% 2820/5312 |
- - |
- - |
| 2025 | 20.29% 2132/4813 |
0.41% 1864/3635 |
2.83% 1324/4076 |
14.54% 2896/4524 |
1.72% 1253/4813 |
| 2024 | 15.79% 883/3463 |
5.73% 336/2808 |
-0.36% 744/3014 |
13.29% 2196/3129 |
-2.99% 2225/3463 |
| 2023 | -7.92% 962/2656 |
0.32% 1745/2280 |
-2.81% 675/2385 |
1.45% 309/2515 |
-6.91% 1975/2655 |
| 2022 | -18.54% 723/2207 |
-11.87% 550/1919 |
4.80% 974/2016 |
-12.64% 748/2113 |
0.95% 1421/2208 |
| 2021 | -2.81% 869/1822 |
-3.30% 798/1255 |
2.71% 992/1330 |
-4.27% 696/1466 |
2.23% 650/1822 |
| 2020 | 20.92% 700/1250 |
-11.27% 830/1028 |
6.97% 852/1067 |
15.09% 236/1164 |
10.70% 583/1184 |
| 2019 | 43.29% 195/1092 |
25.78% 446/754 |
2.34% 89/804 |
1.13% 430/850 |
10.08% 165/918 |
| 2018 | -14.64% 98/834 |
- - |
- - |
- - |
-11.72% 340/691 |
| 2017 | 27.29% 89/714 |
- - |
- - |
- - |
- - |
| 2016 | -5.64% 178/605 |
- - |
- - |
- - |
- - |
| 2015 | -2.28% 265/575 |
- - |
- - |
- - |
- - |
| 2014 | 62.75% 28/237 |
- - |
- - |
- - |
- - |
| 2013 | -13.85% 171/186 |
- - |
- - |
- - |
- - |
| 2012 | 9.00% 45/140 |
- - |
- - |
- - |
- - |
| 2011 | -19.60% 33/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 中海上证50指数增强 VS. 长安沪深300非周期A(740101) |